AngioDynamics Reports Fiscal 2016 Second Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
AngioDynamics (ANGO) PT Cut at Piper Jaffray
January 8, 2016 7:34 AM ESTAngioDynamics (NASDAQ: ANGO) met expectations for its Q2 (Nov) revenues and earnings, but cut guidance for the remainder of the year as the vascular access business has been adjusting to a Q3 recall from last year. Piper Jaffray analyst, Thomas Gunderson, lowered numbers as a result.
The Morpheus product was taken off the market, and the sales force diverted effort to try to retain customers. Not only was retention more... More
AngioDynamics (ANGO) Reports In-Line Q2 EPS; Trims FY16 Outlook
January 7, 2016 4:05 PM ESTAngioDynamics (NASDAQ: ANGO) reported Q2 EPS of $0.14, in-line with the analyst estimate of $0.14. Revenue for the quarter came in at $89.2 million versus the consensus estimate of $88.67 million.
GUIDANCE:
AngioDynamics sees Q3 2016 EPS of $0.10-$0.14, versus the consensus of $0.17. AngioDynamics sees... More
